JP2022536469A - PcrVに結合する抗PcrV抗体、抗PcrV抗体を含む組成物、およびその使用方法 - Google Patents

PcrVに結合する抗PcrV抗体、抗PcrV抗体を含む組成物、およびその使用方法 Download PDF

Info

Publication number
JP2022536469A
JP2022536469A JP2021571690A JP2021571690A JP2022536469A JP 2022536469 A JP2022536469 A JP 2022536469A JP 2021571690 A JP2021571690 A JP 2021571690A JP 2021571690 A JP2021571690 A JP 2021571690A JP 2022536469 A JP2022536469 A JP 2022536469A
Authority
JP
Japan
Prior art keywords
amino acid
seq
antibody
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021571690A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536469A5 (cg-RX-API-DMAC7.html
Inventor
クリストス カラツオス,
アリダ コピ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022536469A publication Critical patent/JP2022536469A/ja
Publication of JP2022536469A5 publication Critical patent/JP2022536469A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021571690A 2019-06-11 2020-06-10 PcrVに結合する抗PcrV抗体、抗PcrV抗体を含む組成物、およびその使用方法 Ceased JP2022536469A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962860146P 2019-06-11 2019-06-11
US62/860,146 2019-06-11
PCT/US2020/037008 WO2020252029A1 (en) 2019-06-11 2020-06-10 Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2022536469A true JP2022536469A (ja) 2022-08-17
JP2022536469A5 JP2022536469A5 (cg-RX-API-DMAC7.html) 2023-06-13

Family

ID=71948699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021571690A Ceased JP2022536469A (ja) 2019-06-11 2020-06-10 PcrVに結合する抗PcrV抗体、抗PcrV抗体を含む組成物、およびその使用方法

Country Status (17)

Country Link
US (3) US11655286B2 (cg-RX-API-DMAC7.html)
EP (1) EP3983015A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022536469A (cg-RX-API-DMAC7.html)
KR (1) KR20220019755A (cg-RX-API-DMAC7.html)
CN (1) CN113966343A (cg-RX-API-DMAC7.html)
AU (1) AU2020292283A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021023335A2 (cg-RX-API-DMAC7.html)
CA (1) CA3140075A1 (cg-RX-API-DMAC7.html)
CL (4) CL2021003215A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021015254A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192810A1 (cg-RX-API-DMAC7.html)
IL (1) IL288727A (cg-RX-API-DMAC7.html)
MA (2) MA54975B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021015156A (cg-RX-API-DMAC7.html)
PH (1) PH12021552903A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112462RA (cg-RX-API-DMAC7.html)
WO (1) WO2020252029A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013070615A1 (en) 2011-11-07 2013-05-16 Medlmmune, Llc. Combination therapies using anti- pseudomonas psl and pcrv binding molecules
FR3114970B1 (fr) * 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
CN114404614B (zh) * 2022-01-28 2024-04-23 上海交通大学 一种靶向铜绿假单胞菌的免疫脂质体及其制备方法和应用
WO2023236041A1 (zh) * 2022-06-07 2023-12-14 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
WO2024206669A2 (en) * 2023-03-29 2024-10-03 Virtuoso Binco, Inc. Antibodies for targeting cd47 and b7h3 and methods of use thereof
EP4735478A1 (en) 2023-06-28 2026-05-06 Universität zu Köln Neutralizing human monoclonal antibodies against p. aeruginosa
CN118530352B (zh) * 2024-05-11 2025-03-25 重庆原伦生物科技有限公司 一种特异性识别铜绿假单胞菌PcrV的抗体及其应用
CN118440191B (zh) * 2024-05-11 2025-06-10 重庆原伦生物科技有限公司 一种抗铜绿假单胞菌PcrV抗体的制备及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010104052A1 (ja) * 2009-03-11 2010-09-16 塩野義製薬株式会社 抗緑膿菌作用を有するヒト化PcrV抗体
JP2015504421A (ja) * 2011-11-07 2015-02-12 メディミューン,エルエルシー 抗シュードモナス属(Pseudomonas)PslおよびPcrV結合分子を用いた併用治療
JP2015535005A (ja) * 2012-11-06 2015-12-07 メディミューン,エルエルシー 抗シュードモナス属(Pseudomonas)PslおよびPcrV結合分子を用いた併用治療
WO2017095744A1 (en) * 2015-11-30 2017-06-08 Medimmune, Llc Method for preventing or treating nosocomial pneumonia
JP2017519768A (ja) * 2014-06-19 2017-07-20 メディミューン,エルエルシー 多細菌性感染の治療

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP4355786B2 (ja) 2001-01-26 2009-11-04 エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド シュードモナスv抗原を用いる免疫化のための方法および組成物
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
SG186017A1 (en) * 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
EP2248826B1 (en) 2008-01-10 2013-06-12 Shionogi&Co., Ltd. Antibody directed against pcrv
ES2370148T3 (es) 2008-01-11 2011-12-13 Eli Lilly & Company (e)-n-{3-[fluoro-11h-10-oxa-1-aza-dibenzo-[a,d]-ciclohepten-5-iliden)-propil]-fenil}-metilsulfonamida como modulador del receptor de glucocorticoides para el tratamiento de artritis reumatoide.
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
WO2012122533A2 (en) 2011-03-10 2012-09-13 The University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
GB201602156D0 (en) 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體
BR112020004977A2 (pt) 2017-09-29 2020-10-06 Regeneron Pharmaceuticals, Inc. moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010104052A1 (ja) * 2009-03-11 2010-09-16 塩野義製薬株式会社 抗緑膿菌作用を有するヒト化PcrV抗体
JP2015504421A (ja) * 2011-11-07 2015-02-12 メディミューン,エルエルシー 抗シュードモナス属(Pseudomonas)PslおよびPcrV結合分子を用いた併用治療
JP2015535005A (ja) * 2012-11-06 2015-12-07 メディミューン,エルエルシー 抗シュードモナス属(Pseudomonas)PslおよびPcrV結合分子を用いた併用治療
JP2017519768A (ja) * 2014-06-19 2017-07-20 メディミューン,エルエルシー 多細菌性感染の治療
WO2017095744A1 (en) * 2015-11-30 2017-06-08 Medimmune, Llc Method for preventing or treating nosocomial pneumonia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF INFECTIOUS DISEASES, vol. 186, JPN6024014896, 2002, pages 64 - 73, ISSN: 0005306430 *

Also Published As

Publication number Publication date
MA56205A (fr) 2022-04-20
MA54975A1 (fr) 2022-05-31
BR112021023335A2 (pt) 2022-01-04
US12552856B2 (en) 2026-02-17
CA3140075A1 (en) 2020-12-17
CL2023003696A1 (es) 2024-06-14
US20260184768A1 (en) 2026-07-02
EA202192810A1 (ru) 2022-03-05
SG11202112462RA (en) 2021-12-30
MX2021015156A (es) 2022-01-18
EP3983015A1 (en) 2022-04-20
US20200392210A1 (en) 2020-12-17
AU2020292283A1 (en) 2021-12-23
WO2020252029A1 (en) 2020-12-17
CL2023003694A1 (es) 2024-06-14
US11655286B2 (en) 2023-05-23
PH12021552903A1 (en) 2022-04-04
CO2021015254A2 (es) 2021-11-19
CL2021003215A1 (es) 2022-09-30
KR20220019755A (ko) 2022-02-17
CL2023003695A1 (es) 2024-06-14
MA54975B1 (fr) 2023-08-31
CN113966343A (zh) 2022-01-21
IL288727A (en) 2022-02-01
US20230322907A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
US11571482B2 (en) Human antibodies to S. aureus Hemolysin A toxin
US11655286B2 (en) Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof
EP2864357B1 (en) Anti-egfr antibodies and uses thereof
US12024556B2 (en) Anti-Staphylococcus antibodies and uses thereof
US20210147519A1 (en) Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
EA047177B1 (ru) АНТИТЕЛА К PcrV, КОТОРЫЕ СВЯЗЫВАЮТ PcrV, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К PcrV, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2964670B1 (en) Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense
EA041355B1 (ru) ЧЕЛОВЕЧЕСКИЕ АНТИТЕЛА К ТОКСИНУ ГЕМОЛИЗИНУ А S.aureus
NZ795857A (en) Human antibodies to S. aureus Hemolysin A toxin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240417

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240620

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240710

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20241122